Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25423189 | 0.89 | NR4A2 (0.34) | NR4A2MEN1KMT2AMITFLMNA | |
| SCHEMBL25748082 | 0.87 | NR4A2 (0.36) | NR4A2MEN1KMT2AMITFLMNA | |
| SCHEMBL25748171 | 0.85 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL25747864 | 0.83 | HTR1A (0.35) | NR4A2LMNAMAPTALDH1A1 | |
| SCHEMBL25436274 | 0.83 | ALDH1A1 (0.38) | NR4A2MEN1KMT2AMITFLMNA | |
| SCHEMBL25748246 | 0.82 | PTPN1 (0.38) | MEN1KMT2AMAPTALDH1A1CYP2C9 | |
| SCHEMBL25438497 | 0.81 | ALDH1A1 (0.39) | NR4A2MEN1KMT2AMITFLMNA | |
| SCHEMBL25422956 | 0.80 | HTR1A (0.47) | LMNAMAPTALDH1A1 | |
| SCHEMBL25425896 | 0.79 | NR4A2 (0.40) | NR4A2MEN1KMT2AMITFLMNA | |
| SCHEMBL17417754 | 0.77 | HSD17B10 (0.43) | NR4A2MEN1KMT2AMITFLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-03-27 | — | — | US | disclosed |
| EP-4452937-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| CN-118715204-A | Compounds of formula (I) | 普赛洛私人有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | NLN, SLC18A2, PYGB | NR4A2 3254/4885MEN1 1401/4885KMT2A 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.